

Radioiodine Therapy for Thyroid Cancer
Objectives of radioiodine therapy for thyroid cancer are presented, and agents, targets and treatment strategies for iodine-refractory thyroid cancer are discussed.
Course ID: Q00422 Category: Radiology Trends for Technologists Modalities: Nuclear Medicine, Radiation Therapy2.0 |
Satisfaction Guarantee |
$24.00
- Targeted CE
- Outline
- Objectives
Targeted CE per ARRT’s Discipline, Category, and Subcategory classification:
[Note: Discipline-specific Targeted CE credits may be less than the total Category A credits approved for this course.]
Nuclear Medicine Technology: 1.00
Procedures: 1.00
Endocrine and Oncology Procedures: 1.00
Outline
- Introduction
- Thyroid Cancer Pathophysiology, Radiobiology, and Demographics
- Current Utilization of Radioactive Iodine Therapy
- Patient Selection
- Dose Selection
- Iodine-Refractory Disease
- Options for Iodine-Refractory Disease
- Reinduction of Iodine Uptake
- Multitargeted Kinase Inhibitors
- Conclusion
Objectives
Upon completion of this course, students will:
- identify which cancer is commonly treated with radioiodine
- be familiar with the role of radioiodine in medullary thyroid cancer
- identify the differentiated thyroid cancer subtypes
- identify the categories of radioiodine use for thyroid cancer
- be familiar with criteria for patient selection for adjuvant therapy
- be familiar with the level of toxicity for thyroid cancer treatment
- be familiar with ATA guidelines for thyroid cancer patients not requiring radioiodine therapy
- identify the criteria for radioactive iodine therapy
- be familiar with the factors taken into account when selecting a radioiodine dose for therapeutic intent
- identify who is credited with the whole-body and blood dosimetry for radioiodine therapy
- identify the radioisotope of iodine that is positron emitting
- identify the drug approved in 2013 for use in iodine-refractory disease
- identify the role of selemetinib in iodine-refractory disease
- understand the role that sorafenib plays in the treatment of iodine-refractory disease
- be familiar with the disadvantages of current targeted therapeutics
- understand the potential 124I PET/CT may have on response to radioiodine therapy